

# Peronne Joseph

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10891273/publications.pdf>

Version: 2024-02-01

9  
papers

524  
citations

1478505

6  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1200  
citing authors

| # | ARTICLE   | IF   | CITATIONS |
|---|---|------|-----------|
| 1 | microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelialâ€mesenchymal transition. Nature Communications, 2014, 5, 2977.         | 12.8 | 226       |
| 2 | Critical role of Wnt/ $\beta$ 2-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget, 2015, 6, 23720-23734.                                   | 1.8  | 158       |
| 3 | Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget, 0, 7, 41637-41649.   | 1.8  | 65        |
| 4 | miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomarkers in Medicine, 2015, 9, 241-257.  | 1.4  | 26        |
| 5 | The miRâ€181aâ€SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer. Cancer Research, 2021, 81, 2044-2055.                           | 0.9  | 21        |
| 6 | Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clinical Cancer Research, 2018, 24, 4588-4601. | 7.0  | 11        |
| 7 | A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. Stem Cell Reports, 2019, 12, 122-134.                 | 4.8  | 8         |
| 8 | Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecologic Oncology, 2018, 151, 525-532.  | 1.4  | 7         |
| 9 | Host and Tumor Factor XII Drive Ovarian Cancer Maintenance and Progression. Blood, 2019, 134, 2384-2384.  | 1.4  | 2         |